1
|
Fernández-Rubio C, Rubio-Hernández M, Alcolea V, Burguete-Mikeo A, Nguewa PA, Pérez-Silanes S. Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression. Antimicrob Agents Chemother 2024; 68:e0155923. [PMID: 38497616 PMCID: PMC10994822 DOI: 10.1128/aac.01559-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Accepted: 02/20/2024] [Indexed: 03/19/2024] Open
Abstract
Leishmaniasis remains one of the main public health problems worldwide, with special incidence in the poorest populations. Selenium and its derivatives can be potent therapeutic options against protozoan parasites. In this work, 17 aryl selenoates were synthesized and screened against three species of Leishmania (Leishmania major, Leishmania amazonensis, and Leishmania infantum). Initial screening in promastigotes showed L. infantum species was more sensitive to selenoderivatives than the others. The lead Se-(2-selenocyanatoethyl) thiophene-2-carboselenoate (16) showed a half-maximal effective concentration of 3.07 µM and a selectivity index > 32.57 against L. infantum promastigotes. It was also the most effective of all 17 compounds, decreasing the infection ratio by 90% in L. infantum-infected macrophages with amastigotes at 10 µM. This aryl selenoate did not produce a hemolytic effect on human red blood cells at the studied doses (10-100 µM). Furthermore, the gene expression of infected murine macrophages related to cell death, the cell cycle, and the selenoprotein synthesis pathway in amastigotes was altered, while no changes were observed in their murine homologs, supporting the specificity of Compound 16 against the parasite. Therefore, this work reveals the possible benefits of selenoate derivatives for the treatment of leishmaniasis.
Collapse
Affiliation(s)
- Celia Fernández-Rubio
- ISTUN Institute of Tropical Health, Department of Microbiology and Parasitology, Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Navarra, Spain
| | - Mercedes Rubio-Hernández
- ISTUN Institute of Tropical Health, Department of Pharmaceutical Sciences, Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain
| | - Verónica Alcolea
- ISTUN Institute of Tropical Health, Department of Pharmaceutical Sciences, Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain
| | - Aroia Burguete-Mikeo
- ISTUN Institute of Tropical Health, Department of Microbiology and Parasitology, Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Navarra, Spain
| | - Paul A. Nguewa
- ISTUN Institute of Tropical Health, Department of Microbiology and Parasitology, Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Navarra, Spain
| | - Silvia Pérez-Silanes
- ISTUN Institute of Tropical Health, Department of Pharmaceutical Sciences, Universidad de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain
| |
Collapse
|
2
|
Henriquez-Figuereo A, Alcon M, Moreno E, Sanmartín C, Espuelas S, Lucio HD, Jiménez-Ruiz A, Plano D. Next generation of selenocyanate and diselenides with upgraded leishmanicidal activity. Bioorg Chem 2023; 138:106624. [PMID: 37295238 DOI: 10.1016/j.bioorg.2023.106624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/08/2023] [Accepted: 05/21/2023] [Indexed: 06/12/2023]
Abstract
Nowadays, leishmaniasis is still treated with outdated drugs that present several obstacles related to their high toxicity, long duration, parenteral administration, high costs and drug resistance. Therefore, there is an urgent demand for safer and more effective novel drugs. Previous studies indicated that selenium compounds are promising derivatives for innovative therapy in leishmaniasis treatment. With this background, a new library of 20 selenocyanate and diselenide derivatives were designed based on structural features present in the leishmanicidal drug miltefosine. Compounds were initially screened against promastigotes of L. major and L. infantum and their cytotoxicity was evaluated in THP-1 cells. Compounds B8 and B9 were the most potent and less cytotoxic and were further screened for the intracellular back transformation assay. The results obtained revealed that B8 and B9 showed EC50 values of 7.7 µM and 5.7 µM, respectively, in L. major amastigotes, while they presented values of 6.0 µM and 7.4 µM, respectively, against L. infantum amastigotes. Furthermore, they exerted high selectivity (60 < SI > 70) towards bone marrow-derived macrophages. Finally, these compounds exhibited higher TryR inhibitory activity than mepacrine (IC50 7.6 and 9.2 µM, respectively), and induced nitric oxide (NO) and reactive oxygen species (ROS) production in macrophages. These results suggest that the compounds B8 and B9 could not only exert a direct leishmanicidal activity against the parasite but also present an indirect action by activating the microbicidal arsenal of the macrophage. Overall, these new generation of diselenides could constitute promising leishmanicidal drug candidates for further studies.
Collapse
Affiliation(s)
- Andreina Henriquez-Figuereo
- University of Navarra, Faculty of Pharmacy and Nutrition, Department of Pharmaceutical Technology and Chemistry, Pamplona, Spain; Institute of Tropical Health, University of Navarra, ISTUN, Pamplona, Spain
| | - Mercedes Alcon
- Universidad de Alcalá, Departamento de Biología de Sistemas, 28805 Alcalá de Henares, Madrid, Spain
| | - Esther Moreno
- University of Navarra, Faculty of Pharmacy and Nutrition, Department of Pharmaceutical Technology and Chemistry, Pamplona, Spain; Institute of Tropical Health, University of Navarra, ISTUN, Pamplona, Spain; IdisNA, Navarra Institute for Health Research, Pamplona, Spain.
| | - Carmen Sanmartín
- University of Navarra, Faculty of Pharmacy and Nutrition, Department of Pharmaceutical Technology and Chemistry, Pamplona, Spain; Institute of Tropical Health, University of Navarra, ISTUN, Pamplona, Spain; IdisNA, Navarra Institute for Health Research, Pamplona, Spain.
| | - Socorro Espuelas
- University of Navarra, Faculty of Pharmacy and Nutrition, Department of Pharmaceutical Technology and Chemistry, Pamplona, Spain; Institute of Tropical Health, University of Navarra, ISTUN, Pamplona, Spain; IdisNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Héctor de Lucio
- Universidad de Alcalá, Departamento de Biología de Sistemas, 28805 Alcalá de Henares, Madrid, Spain
| | - Antonio Jiménez-Ruiz
- Universidad de Alcalá, Departamento de Biología de Sistemas, 28805 Alcalá de Henares, Madrid, Spain
| | - Daniel Plano
- University of Navarra, Faculty of Pharmacy and Nutrition, Department of Pharmaceutical Technology and Chemistry, Pamplona, Spain; Institute of Tropical Health, University of Navarra, ISTUN, Pamplona, Spain; IdisNA, Navarra Institute for Health Research, Pamplona, Spain
| |
Collapse
|
3
|
Galarreta-Rodriguez I, Etxebeste-Mitxeltorena M, Moreno E, Plano D, Sanmartín C, Megahed S, Feliu N, Parak WJ, Garaio E, Gil de Muro I, Lezama L, Ruiz de Larramendi I, Insausti M. Preparation of Selenium-Based Drug-Modified Polymeric Ligand-Functionalised Fe 3O 4 Nanoparticles as Multimodal Drug Carrier and Magnetic Hyperthermia Inductor. Pharmaceuticals (Basel) 2023; 16:949. [PMID: 37513861 PMCID: PMC10385492 DOI: 10.3390/ph16070949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 06/20/2023] [Accepted: 06/27/2023] [Indexed: 07/30/2023] Open
Abstract
In recent years, much effort has been invested into developing multifunctional drug delivery systems to overcome the drawbacks of conventional carriers. Magnetic nanoparticles are not generally used as carriers but can be functionalised with several different biomolecules and their size can be tailored to present a hyperthermia response, allowing for the design of multifunctional systems which can be active in therapies. In this work, we have designed a drug carrier nanosystem based on Fe3O4 nanoparticles with large heating power and 4-amino-2-pentylselenoquinazoline as an attached drug that exhibits oxidative properties and high selectivity against a variety of cancer malignant cells. For this propose, two samples composed of homogeneous Fe3O4 nanoparticles (NPs) with different sizes, shapes, and magnetic properties have been synthesised and characterised. The surface modification of the prepared Fe3O4 nanoparticles has been developed using copolymers composed of poly(ethylene-alt-maleic anhydride), dodecylamine, polyethylene glycol and the drug 4-amino-2-pentylselenoquinazoline. The obtained nanosystems were properly characterised. Their in vitro efficacy in colon cancer cells and as magnetic hyperthermia inductors was analysed, thereby leaving the door open for their potential application as multimodal agents.
Collapse
Affiliation(s)
- Itziar Galarreta-Rodriguez
- Departamento Química Orgánica e Inorgánica, Facultad de Ciencia y Tecnología, University of the Basque Country (UPV/EHU), Sarriena s/n, 48940 Leioa, Spain
| | - Mikel Etxebeste-Mitxeltorena
- Department of Pharmaceutical Technology and Chemistry, University of Navarra, Irunlarrea 1, 31008 Pamplona, Spain
- The Navarra Medical Research Institute (IdiSNA), Irunlarrea 3, 31008 Pamplona, Spain
| | - Esther Moreno
- Tropical Health Institute of the University of Navarra (ISTUN), University of Navarra, Irunlarrea 1, 31008 Pamplona, Spain
- Fachbereich Physik, Universität Hamburg, 22761 Hamburg, Germany
- Physics Department, Faculty of Science, Al-Azhar University, Cairo 11884, Egypt
| | - Daniel Plano
- Department of Pharmaceutical Technology and Chemistry, University of Navarra, Irunlarrea 1, 31008 Pamplona, Spain
- The Navarra Medical Research Institute (IdiSNA), Irunlarrea 3, 31008 Pamplona, Spain
| | - Carmen Sanmartín
- Department of Pharmaceutical Technology and Chemistry, University of Navarra, Irunlarrea 1, 31008 Pamplona, Spain
- The Navarra Medical Research Institute (IdiSNA), Irunlarrea 3, 31008 Pamplona, Spain
| | - Saad Megahed
- Fachbereich Physik, Universität Hamburg, 22761 Hamburg, Germany
- Physics Department, Faculty of Science, Al-Azhar University, Cairo 11884, Egypt
| | - Neus Feliu
- Center for Applied Nanotechnology CAN, Fraunhofer Institute for Applied Polymer Research IAP, 20146 Hamburg, Germany
| | | | - Eneko Garaio
- Departamento de Ciencias, Universidad Pública de Navarra, Campus Arrosadía, 31006 Pamplona, Spain
- Institute for Advanced Materials and Mathematics (INAMAT2), Universidad Pública de Navarra, Campus de Arrosadía, 31006 Pamplona, Spain
| | - Izaskun Gil de Muro
- Departamento Química Orgánica e Inorgánica, Facultad de Ciencia y Tecnología, University of the Basque Country (UPV/EHU), Sarriena s/n, 48940 Leioa, Spain
- BCMaterials, Basque Center for Materials, Applications and Nanostructures, UPV/EHU Science Park, 48940 Leioa, Spain
| | - Luis Lezama
- Departamento Química Orgánica e Inorgánica, Facultad de Ciencia y Tecnología, University of the Basque Country (UPV/EHU), Sarriena s/n, 48940 Leioa, Spain
| | - Idoia Ruiz de Larramendi
- Departamento Química Orgánica e Inorgánica, Facultad de Ciencia y Tecnología, University of the Basque Country (UPV/EHU), Sarriena s/n, 48940 Leioa, Spain
| | - Maite Insausti
- Departamento Química Orgánica e Inorgánica, Facultad de Ciencia y Tecnología, University of the Basque Country (UPV/EHU), Sarriena s/n, 48940 Leioa, Spain
- BCMaterials, Basque Center for Materials, Applications and Nanostructures, UPV/EHU Science Park, 48940 Leioa, Spain
| |
Collapse
|
4
|
Santana Filho PC, Brasil da Silva M, Malaquias da Silva BN, Fazolo T, Dorneles GP, Braun de Azeredo J, Alf da Rosa M, Rodrigues Júnior LC, Peres A, Santos Canto RF, Torres Romão PR. Seleno-indoles trigger reactive oxygen species and mitochondrial dysfunction in Leishmania amazonensis. Tetrahedron 2023. [DOI: 10.1016/j.tet.2023.133329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
5
|
Organoselenocyanates Tethered Methyl Anthranilate Hybrids with Promising Anticancer, Antimicrobial, and Antioxidant Activities. INORGANICS 2022. [DOI: 10.3390/inorganics10120246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Novel methyl anthranilate-based organoselenocyanate hybrids were developed, and their structures were confirmed by the state-of-the-art spectroscopic techniques. Their antimicrobial potency was estimated against various microbial strains (e.g., Candida albicans, Escherichia coli, and Staphylococcus aureus). The S. aureus and C. albicans strains were more sensitive than E. coli toward the organoselenocyanates. Interestingly, the azoic derivatives 4 and 9, methyl ester 6, and phenoxy acetamide 15 showed promising antimicrobial activity. Moreover, the antitumor potential was estimated against liver and breast carcinomas, as well as primary fibroblasts. Interestingly, the anticancer properties were more pronounced in the HepG2 cells. The organoselenocyanates 4, 6, 9, 10, and 15 showed interesting anti-HepG2 cytotoxic patterns. Additionally, organoselenocyanates 3, 4, and 10 exhibited promising antioxidant activities in the 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid and 2,2-diphenyl-1-picrylhydrazyl in vitro assays compared to ascorbic acid. These data point to promising antimicrobial, anticancer, and antioxidant activities of organoselenocyanates 6, 9, and 15 warrant further studies.
Collapse
|
6
|
Ramos-Inza S, Henriquez-Figuereo A, Moreno E, Berzosa M, Encío I, Plano D, Sanmartín C. Unveiling a New Selenocyanate as a Multitarget Candidate with Anticancer, Antileishmanial and Antibacterial Potential. Molecules 2022; 27:7477. [PMID: 36364304 PMCID: PMC9656702 DOI: 10.3390/molecules27217477] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 10/28/2022] [Indexed: 09/02/2023] Open
Abstract
Currently, cancer, leishmaniasis and bacterial infections represent a serious public health burden worldwide. Six cinnamyl and benzodioxyl derivatives incorporating selenium (Se) as selenocyanate, diselenide, or selenide were designed and synthesized through a nucleophilic substitution and/or a reduction using hydrides. Ferrocene was also incorporated by a Friedel–Crafts acylation. All the compounds were screened in vitro for their antiproliferative, antileishmanial, and antibacterial properties. Their capacity to scavenge free radicals was also assessed as a first approach to test their antioxidant activity. Benzodioxyl derivatives 2a –b showed cytotoxicity against colon (HT-29) and lung (H1299) cancer cell lines, with IC50 values below 12 µM, and were also fairly selective when tested in nonmalignant cells. Selenocyanate compounds 1 –2a displayed potent antileishmanial activity in L. major and L. infantum , with IC50 values below 5 µM. They also exhibited antibacterial activity in six bacterial strains, notably in S. epidermidis with MIC and MBC values of 12.5 µg/mL. Ferrocene-containing selenide 2c was also identified as a potent antileishmanial agent with radical scavenging activity. Remarkably, derivative 2a with a selenocyanate moiety was found to act as a multitarget compound with antiproliferative, leishmanicidal, and antibacterial activities. Thus, the current work showed that 2a could be an appealing scaffold to design potential therapeutic drugs for multiple pathologies.
Collapse
Affiliation(s)
- Sandra Ramos-Inza
- Department of Pharmaceutical Technology and Chemistry, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 Pamplona, Spain
| | - Andreina Henriquez-Figuereo
- Department of Pharmaceutical Technology and Chemistry, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
- Institute of Tropical Health of the University of Navarra (ISTUN), University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
| | - Esther Moreno
- Department of Pharmaceutical Technology and Chemistry, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 Pamplona, Spain
- Institute of Tropical Health of the University of Navarra (ISTUN), University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
| | - Melibea Berzosa
- Institute of Tropical Health of the University of Navarra (ISTUN), University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
- Department of Microbiology and Parasitology, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
| | - Ignacio Encío
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 Pamplona, Spain
- Department of Health Sciences, Public University of Navarra, Avda. Barañain s/n, E-31008 Pamplona, Spain
| | - Daniel Plano
- Department of Pharmaceutical Technology and Chemistry, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 Pamplona, Spain
- Institute of Tropical Health of the University of Navarra (ISTUN), University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
| | - Carmen Sanmartín
- Department of Pharmaceutical Technology and Chemistry, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Irunlarrea 3, E-31008 Pamplona, Spain
- Institute of Tropical Health of the University of Navarra (ISTUN), University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain
| |
Collapse
|
7
|
Wang J, Lu XX, Yang RP, Xiang ZH, Zhang BB, Chao S, Liu L, Yan Y, Shang X. Synthesis of Spiro[5.5]trienones- and Spiro[4.5]trienones-Fused Selenocyanates via Electrophilic Selenocyanogen Cyclization and Dearomative Spirocyclization. J Org Chem 2022; 87:13089-13101. [PMID: 36170059 DOI: 10.1021/acs.joc.2c01594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A practical strategy for the synthesis of spiro[5.5]trienones-fused selenocyanates and spiro[4.5]trienones-fused selenocyanates through electrophilic selenocyanogen cyclization and dearomative spirocyclization is reported. This approach was conducted under mild conditions with broad substrate scope and good functional group tolerance. The utility of this procedure is exhibited in the late-stage functionalization of nature product and drug molecules.
Collapse
Affiliation(s)
- Jia Wang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| | - Xiao-Xiao Lu
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| | - Run-Ping Yang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| | - Zhi-Hao Xiang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| | - Bing-Bing Zhang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| | - Shujun Chao
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| | - Lixia Liu
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| | - Yunhui Yan
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| | - Xuefang Shang
- School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, China
| |
Collapse
|
8
|
Rubio-Hernández M, Alcolea V, Pérez-Silanes S. Potential of sulfur-selenium isosteric replacement as a strategy for the development of new anti-chagasic drugs. Acta Trop 2022; 233:106547. [PMID: 35667455 DOI: 10.1016/j.actatropica.2022.106547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Revised: 05/31/2022] [Accepted: 06/01/2022] [Indexed: 11/25/2022]
Abstract
Current treatment for Chagas disease is based on only two drugs: benznidazole and nifurtimox. Compounds containing sulfur (S) in their structure have shown promising results in vitro and in vivo against Trypanosoma cruzi, the parasite causing Chagas disease. Notably, some reports show that the isosteric replacement of S by selenium (Se) could be an interesting strategy for the development of new compounds for the treatment of Chagas disease. To date, the activity against T. cruzi of three Se- containing groups has been compared with their S counterparts: selenosemicarbazones, selenoquinones, and selenocyanates. More studies are needed to confirm the positive results of Se compounds. Therefore, we have investigated S compounds described in the literature tested against T. cruzi. We focused on those tested in vivo that allowed isosteric replacement to propose their Se counterparts as promising compounds for the future development of new drugs against Chagas disease.
Collapse
|
9
|
Monte Neto RLD, Moreira POL, de Sousa AM, Garcia MADN, Maran SR, Moretti NS. Antileishmanial metallodrugs and the elucidation of new drug targets linked to post-translational modifications machinery: pitfalls and progress. Mem Inst Oswaldo Cruz 2022; 117:e210403. [PMID: 35320824 PMCID: PMC8944189 DOI: 10.1590/0074-02760220403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 01/17/2022] [Indexed: 11/29/2022] Open
Abstract
Despite the increasing number of manuscripts describing potential alternative antileishmanial compounds, little is advancing on translating these knowledges to new products to treat leishmaniasis. This is in part due to the lack of standardisations during pre-clinical drug discovery stage and also depends on the alignment of goals among universities/research centers, government and pharmaceutical industry. Inspired or not by drug repurposing, metal-based antileishmanial drugs represent a class that deserves more attention on its use for leishmaniasis chemotherapy. Together with new chemical entities, progresses have been made on the knowledge of parasite-specific drug targets specially after using CRISPR/Cas system for functional studies. In this regard, Leishmania parasites undergoe post-translational modification as key regulators in several cellular processes, which represents an entire new field for drug target elucidation, once this is poorly explored. This perspective review describes the advances on antileishmanial metallodrugs and the elucidation of drug targets based on post-translational modifications, highlighting the limitations on the drug discovery/development process and suggesting standardisations focused on products addressed to who need it most.
Collapse
Affiliation(s)
- Rubens Lima do Monte Neto
- Fundação Oswaldo Cruz-Fiocruz, Instituto René Rachou, Grupo de Pesquisas em Biotecnologia Aplicada ao Estudo de Patógenos, Belo Horizonte, MG, Brasil
| | - Paulo Otávio Lourenço Moreira
- Fundação Oswaldo Cruz-Fiocruz, Instituto René Rachou, Grupo de Pesquisas em Biotecnologia Aplicada ao Estudo de Patógenos, Belo Horizonte, MG, Brasil
| | - Alessandra Mara de Sousa
- Fundação Oswaldo Cruz-Fiocruz, Instituto René Rachou, Grupo de Pesquisas em Biotecnologia Aplicada ao Estudo de Patógenos, Belo Horizonte, MG, Brasil
| | - Miguel Antonio do Nascimento Garcia
- Universidade Federal de São Paulo, Departamento de Microbiologia, Imunologia e Parasitologia, Laboratório de Biologia Molecular de Patógenos, São Paulo, SP, Brasil
| | - Suellen Rodrigues Maran
- Universidade Federal de São Paulo, Departamento de Microbiologia, Imunologia e Parasitologia, Laboratório de Biologia Molecular de Patógenos, São Paulo, SP, Brasil
| | - Nilmar Silvio Moretti
- Universidade Federal de São Paulo, Departamento de Microbiologia, Imunologia e Parasitologia, Laboratório de Biologia Molecular de Patógenos, São Paulo, SP, Brasil
| |
Collapse
|
10
|
Selenium and protozoan parasitic infections: selenocompounds and selenoproteins potential. Parasitol Res 2022; 121:49-62. [PMID: 34993638 PMCID: PMC8735723 DOI: 10.1007/s00436-021-07400-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 11/29/2021] [Indexed: 12/17/2022]
Abstract
The current drug treatments against protozoan parasitic diseases including Chagas, malaria, leishmaniasis, and toxoplasmosis represent good examples of drug resistance mechanisms and have shown diverse side effects. Therefore, the identification of novel therapeutic strategies and drug compounds against such life-threatening diseases is urgent. According to the successful usage of selenium (Se) compounds-based therapy against some diseases, this therapeutic strategy has been recently further underlined against these parasitic diseases by targeting different parasite´s essential pathways. On the other hand, due to the important functions played by parasite selenoproteins in their biology (such as modulating the host immune response), they can be also considered as a novel therapeutic strategy by designing specific inhibitors against these important proteins. In addition, the immunomodulatory potentiality of these compounds to trigger T helper type 1 (Th1) cells and cytokine-mediated immune response for the substantial induction of proinflammatory cytokines, thus, Se, selenoproteins, and parasite selenoproteins could be further investigated to find possible vaccine antigens. Herein, we collect and present the results of some studies regarding Se-based therapy against protozoan parasitic diseases and highlight relevant information and some viewpoints that might be insightful to advance toward more effective studies in the future.
Collapse
|
11
|
Monte Neto RLD, Moreira POL, de Sousa AM, Garcia MADN, Maran SR, Moretti NS. Antileishmanial metallodrugs and the elucidation of new drug targets linked to post-translational modifications machinery: pitfalls and progress. Mem Inst Oswaldo Cruz 2022. [DOI: 10.1590/0074-02760210403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|